Clinical Trial Update: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating adjuvant abemaciclib in combination with standard endocrine therapy versus standard therapy alone in high-risk HR+/HER2- early bre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: West German Study Group | Conditions: Breast Cancer Female | Phase 3 | Status: ACTIVE_NOT_RECRUITING